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Objective. To identify serum protein biomarkers
specific for rheumatoid arthritis (RA), using surface-
enhanced laser desorption/ionization time-of-flight
mass spectrometry (SELDI-TOF-MS) technology.
Methods. A total of 103 serum samples from
patients and healthy controls were analyzed. Thirty-four
of the patients had a diagnosis of RA, based on the
American College of Rheumatology criteria. The inflam-
mation control group comprised 20 patients with psori-
atic arthritis (PsA), 9 with asthma, and 10 with Crohn’s
disease. The noninflammation control group comprised
14 patients with knee osteoarthritis and 16 healthy
control subjects. Serum protein profiles were obtained
by SELDI-TOF-MS and compared in order to identify
new biomarkers specific for RA. Data were analyzed by
a machine learning algorithm called decision tree boost-
ing, according to different preprocessing steps.
Results. The most discriminative mass/charge
(m/z) values serving as potential biomarkers for RA
were identified on arrays for both patients with RA
versus controls and patients with RA versus patients
with PsA. From among several candidates, the following
peaks were highlighted: m/z values of 2,924 (RA versus
controls on H4 arrays), 10,832 and 11,632 (RA versus
controls on CM10 arrays), 4,824 (RA versus PsA on H4
arrays), and 4,666 (RA versus PsA on CM10 arrays).
Positive results of proteomic analysis were associated
with positive results of the anti–cyclic citrullinated
peptide test. Our observations suggested that the 10,832
peak could represent myeloid-related protein 8.
Conclusion. SELDI-TOF-MS technology allows
rapid analysis of many serum samples, and use of
decision tree boosting analysis as the main statistical
method allowed us to propose a pattern of protein peaks
specific for RA.
Rheumatoid arthritis (RA) is a chronic auto-
immune disease of unknown etiology. RA is character-
ized by the development of synovitis, which is directly
responsible for cartilage and bone degradation in mul-
tiple joints. Early identification of pathologic synovitis is
of major importance, because synovitis represents the
primary location of the inflammatory process in the
rheumatoid joint and is a target for therapy (1,2). Two
different approaches to such early identification have
recently been developed.
The aim of the first approach is to directly evaluate
synovial inflammation by means of new morphologic
and/or metabolic imaging techniques such as high-
resolution ultrasonography, fat-suppressed gadolinium-
enhanced magnetic resonance imaging, and positron
emission tomography with 18F-fluorodeoxyglucose (3).
The aim of the second approach is to identify specific
biomarkers of the disease in the synovial fluid or serum.
The recent discovery of an antibody response to citrul-
linated peptides in the serum of patients with RA
illustrates this concept. With a sensitivity of 76% and
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a specificity of nearly 96%, identification of antibodies
against cyclic citrullinated peptide (CCP) has strong
clinical relevance (4) in patients with established dis-
eases but is also a prognostic factor for progression of
undifferentiated arthritis into RA (5). In some individ-
uals, however, anti-CCP positivity years before the oc-
currence of any clinical symptoms (6) suggests that it
reflects both latent and patent forms of RA and, there-
fore, not simply the pathophysiologic process. Routine
measurements of IgM, IgG, and IgA rheumatoid factor
(RF) may also be of some help in the diagnosis of RA
(7,8), but these markers classically appear late in the
course of disease and are less specific. There remains a
clear need for the identification of other specific biomar-
kers of RA that would allow an early and specific
diagnosis of the disease.
Protein differential display techniques such as
2-dimensional (2-D) gel electrophoresis, 1-D or 2-D
liquid chromatography mass spectometry (MS), or
surface-enhanced laser desorption/ionization time-of-
flight MS (SELDI-TOF-MS) have become increasingly
useful to establish fingerprint profiles of both disease
and control states in large numbers of samples (9).
Serum, plasma, urine, intestinal fluid, cell lysates, or
cellular secretion products contain several thousand
proteins or peptides that regulate a vast number of
physiologic functions and may be related to pathology.
Identification of protein patterns in these body fluids
could allow a valid clinical diagnosis to be made before
the onset of symptoms. Separation and characterization
of complex protein mixtures are certainly not easy tasks,
but each technique seems to have its own potential for
reaching this goal.
SELDI-TOF-MS is a rapid and sensitive method
that allows a large number of samples to be measured
simultaneously in a relatively short period of time (10–
12). Small sample volume is required, and the Protein-
Chip system appears suitable for profiling low molecular
weight proteins. This system is currently used to identify
biomarkers in the blood of patients with various cancers
at different stages (13–19).
The SELDI-TOF-MS approach uses a variety of
selective chips composed of different chromatographic,
chemically active surfaces (anionic, cationic, hydropho-
bic, hydrophilic, or metal ion) on which a biologic
sample (such as serum) is applied. On ProteinChip
array, proteins are captured by, for example, Lewis
acid–basis interaction, charge, hydrophobicity, or chro-
matographic affinity. Hence, each surface preferentially
binds a particular class of protein based on its physio-
chemical properties and gives rise to a specific pattern.
After several washes to eliminate nonspecific interac-
tions, proteins are cocrystallized with an excess of
energy-absorbing matrix molecules. A laser desorbs and
ionizes the proteins. Ions are detected and, on a typical
spectrum, are displayed with the corresponding mass/
charge (m/z) ratio as a peak, the amplitude or area of
which is proportional to protein abundance.
Here, we describe how SELDI-TOF-MS, when
applied to serum, may generate complex protein profiles
and how appropriate biostatistical analysis may select
marker profiles specific to RA. For that purpose,
SELDI-TOF-MS analyses of RA sera were compared
with analyses of sera obtained from normal healthy
subjects and from patients with noninflammatory rheu-
matic disease, such as osteoporosis (OA) (negative
controls). The analyses were also compared with those
performed on sera from patients with psoriatic arthritis
(PsA), another immune-mediated inflammatory rheu-
matic disease, and from patients with immune-mediated
inflammatory nonrheumatic diseases such as asthma and
Crohn’s disease (positive controls).
PATIENTS AND METHODS
Patients. This study was approved by the ethics com-
mittee of our academic hospital. A total of 103 serum samples
from patients affected by various pathologies and from healthy
controls were collected prospectively (from the beginning of
2002 until the end of 2003) into 10-ml Serum Separator
Vacutainer tubes (Becton Dickinson, Franklin Lakes, NJ) and
centrifuged at 3,000 rpm for 10 minutes. All sera were ali-
quoted and immediately frozen at 80°C until thawed specif-
ically for SELDI-TOF-MS analysis. All of the individuals from
whom serum samples were collected were Caucasian.
Thirty-four of the blood samples were obtained from
patients fulfilling the 1987 American College of Rheumatology
(formerly, the American Rheumatism Association) criteria for
RA (20). Among the 34 patients with RA, 22 (65%) were
women, the mean age was 52 years (range 26–79 years), and
the mean disease duration was 8.8 years (range 0.5–22 years)
(Table 1). IgM-RF positivity was observed in 26 (76%) of 34
patients. The mean C-reactive protein (CRP) serum level was
19 mg/liter (range 3–90 mg/liter). Concomitant treatments
included methotrexate (MTX) at a mean dosage of 11.7
mg/week (range 5–20 mg/week) in 20 (59%) of 34 patients, and
prednisolone at a mean dosage of 7 mg/day in 16 (47%) of 34
patients. The mean numbers of tender and swollen joints were
15 (range 6–32) and 11 (range 6–23), respectively. All patients
were considered to have active disease because they exhibited
at least 6 tender and swollen joints, which is the classically
accepted criterion.
The inflammation control group comprised 20 patients
with PsA, 9 with asthma, and 10 with Crohn’s disease. Among
the 20 patients with PsA, 10 (50%) were women, the mean age
was 44 years (range 21–65 years), and the mean disease
duration was 8.4 years (range 0.5–30 years). The mean CRP
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serum level was 18 mg/liter (range 0.7–69 mg/liter). Concom-
itant treatments included MTX at a mean dosage of 15.6
mg/week (range 10–25 mg/week) in 8 (40%) of 20 patients, and
prednisolone at a mean dosage of 5 mg/day in 5 (25%) of 20
patients. The mean numbers of tender and swollen joints were
15 (range 3–33) and 11 (range 5–18), respectively. All patients
were considered to have active disease because they exhibited
at least 3 tender and swollen joints, which is the classically
accepted criterion. Patients in the other positive control groups
(asthma and Crohn’s disease) were matched for age and sex
with patients in the RA group.
Negative controls were 14 patients with knee OA and
16 unaffected healthy subjects, all of whom were age- and
sex-matched with patients with RA.
The 103 serum samples were analyzed by an anti-CCP2
antibody enzyme-linked immunosorbent assay (ELISA; Euro-
immun, Lubeck, Germany), according to manufacturer’s in-
structions; the cutoff was 5 relative units/ml. Of the 34 patients
with RA, 28 had positive results of the anti-CCP test. One
serum sample (obtained from a healthy subject in the control
group) was positive by anti-CCP testing. Thus, the sensitivity
and specificity of this ELISA, based on the 103 serum samples,
were calculated to be 82% and 98%, respectively.
A serum sample obtained from a healthy control
subject was used as a quality control sample. It was used to
determine reproducibility and as a control protein profile for
each SELDI-TOF-MS experiment.
ProteinChip array preparation and analysis. Several
chip arrays (Ciphergen Biosystems, Fremont, CA), including a
strong anion-exchange surface (Q10), weak cation-exchange
surface (CM10), or a hydrophobic surface (H4), were tested in
order to determine the optimal profile in terms of the number
and resolution of peaks. The pH (range 3–9) and salt concen-
tration (range 30 mM to 1M) in washing buffers were opti-
mized using ion-exchange arrays. The percentage of acetoni-
trile (ACN) (0–60%) was optimized for the H4 arrays. CM10
and H4 arrays were ultimately selected to give the best
results. A pH value of 4 and 10% ACN were finally chosen
as optimal conditions for serum analysis. The amount of
proteins loaded onto the arrays was first optimized by
diluting the serum from 1-fold to 70-fold in the correspond-
ing binding buffer. Dilutions of 5-fold and 35-fold were
selected as optimal conditions for CM10 and H4 arrays,
respectively (data not shown).
Prior to sample loading, each spot of the H4 arrays was
circled with a Pap pen (Zymed Laboratories, South San
Francisco, CA). The CM10 and H4 arrays were activated with
10 l of 10 mM HCl and 5 l of ACN, respectively, and
equilibrated with 10 l of binding buffer (for CM10, 100 mM
acetate, 30 mM NaCl [pH 4]; for H4, phosphate buffered saline
[PBS], ACN 10%, and trifluoroacetic acid [TFA] 0.1%) for 5
minutes. Serum samples for SELDI-TOF-MS analysis were
prepared by diluting 10 l of serum with 40 l of 100 mM
acetate buffer (pH 4) for CM10 experiments and with 340 l of
PBS, ACN 10%, and TFA 0.1% for H4 experiments. Five
microliters of each diluted serum mixture was applied, in
duplicate, to a ProteinChip array and incubated for 1 hour at
room temperature. After discarding the remaining sample, the
CM10 and H4 arrays were washed 4 times and 2 times,
respectively, with 10 l of binding buffer for 5 minutes,
followed by 2 (for CM10) and 4 (for H4) brief rinses with
distilled water. The chips were air-dried and stored in the dark
at room temperature until subjected to SELDI-TOF-MS ana-
lysis. A matrix solution (-cyano-4-hydroxycinnamic acid
[CHCA]) (Ciphergen Biosystems) was prepared according to
the manufacturer’s instructions in 50% volume/volume ACN
and 0.5% TFA. Before SELDI-TOF-MS analysis, 1 l of the
saturated CHCA solution was applied onto each CM10 spot,
and 1 l of a 1:2 dilution was loaded twice on the H4 array and
allowed to air dry.
Chips were read on a Protein Biological System II
ProteinChip reader (Ciphergen Biosystems). All spectra were
acquired in a positive mode and generated by averaging 130
laser shots at a laser intensity of 200 and 210, and a sensitivity
of 8 and 9, for the CM10 and H4 arrays, respectively. The focus
mass was set to 10,250 daltons.
Mass accuracy was calibrated externally using the
All-in-1 Peptide Standard (Ciphergen Biosystems) comple-
mented by myoglobin (MW 16,951.5) and cytochrome c (MW
12,360) in order to cover a larger range of mass (0–20,000
daltons). Calibration was carried out according to the manu-
facturer’s instructions (21).
Table 1. Epidemiologic characteristics of the patients and controls*
Characteristic RA PsA Negative control
Age, years 52 (26–79) 44 (21–65) 45 (21–77)
% women 65 50 61
Disease duration, years 8.8 (0.5–22) 8.4 (0.5–30) –
Serum CRP level, mg/liter 19 (3–90) 18 (0.7–69) –
Concomitant therapy
Methotrexate, mg/week† 11.7 (5–20) 15.6 (10–25) –
Prednisolone, mg/day‡ 7 5 –
No. of tender joints 15 (6–32) 15 (3–33) –
No. of swollen joints 11 (6–23) 11 (5–18) –
% anti-CCP2 antibody positive 82 0 3.30
* Except where indicated otherwise, values are the mean (range). Anti–cyclic citrullinated peptide 2
(anti-CCP2) antibodies were detected by enzyme-linked immunosorbent assay. RA  rheumatoid
arthritis; PsA  psoriatic arthritis; CRP  C-reactive protein.
† Methotrexate was being received by 59% of the patients with RA and by 40% of the patients with PsA.
‡ Prednisolone was being received by 47% of the patients with RA and by 25% of the patients with PsA.
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Preprocessing. Before data were analyzed, several
processing steps were required, including baseline subtraction,
normalization, or peak detection. Baseline subtraction was
achieved by using a varying-width segmented convex hull
algorithm that eliminates any baseline signal caused mostly by
matrix distortions (21). All data were normalized according to
the total ion current normalization function, by following the
software instructions. Spectrum m/z values of 1,000 were not
used for analysis, because the energy-absorbing matrix signal
generally interfered with peak detection in this area. Due to
biologic or technical reasons, there were further variations in
the exact horizontal position of the same biologic peak from
one spectrum to another. Thus, further preprocessing was
necessary to reduce the dimensionality of the data and to take
this noise into account. Two different approaches were con-
sidered.
In the first approach, peak detection was performed
using ProteinChip Biomarker Wizard software version 3.0 (Ci-
phergen Biosystems). Peaks having an m/z ratio between 1,000
and 20,000 were autodetected with a signal-to-noise ratio of
3, and the peaks were clustered using second-pass peak
selection with a signal-to-noise ratio of 2 and a 0.3% mass
window.
In the second approach, the m/z axis was divided into
nonoverlapping intervals whose sizes were increasing propor-
tionally with the m/z values, and the intensity associated to
each interval was taken as the sum of the intensities over the
interval. The size of an interval starting at mass/charge m is
computed as m.r, with r representing the parameter that
determines the number of inputs that were used for the
statistical analysis. Three r values were tested: 0.3%, 0.5%, and
1%. Unlike peak detection as carried out with ProteinChip
Biomarker Wizard software, this second approach did not
imply any filtering of the peaks; all m/z intervals were con-
served as inputs for the statistical analysis.
Statistical analysis. Decision tree boosting. The data
were analyzed by a machine learning algorithm called decision
tree boosting. The decision tree method (22) is among the
most popular of the learning algorithms, and it has already
been used to analyze SELDI-TOF-MS measurements (23,24).
A decision tree is a classification model represented by a tree
in which each interior node is labeled with a test that compares
an m/z value with an intensity threshold, and each terminal
node is labeled with the name of a class. To retrieve the
classification of a new patient, data generated by the (pre-
processed) spectrum, which is related to his or her serum, are
propagated into the tree by answering to the tests until a leaf
node is reached, and the patient is classified according to the
class label attached to that leaf. One drawback of this method
is that it is highly unstable. A small modification of the set of
patients may lead to a quite different tree. Hence, the predic-
tion given by a single decision tree may not be very reliable.
This instability translates into accuracy that usually is lower
than that of other machine learning algorithms.
One very efficient way by which to circumvent this
instability and improve decision tree accuracy is to use the
ensemble method. According to this method, several trees are
built instead of only 1, a classifier is defined by aggregating the
classes predicted by these trees; the classification attributed to
a new patient is represented by the majority class among
classes predicted by all trees of the ensemble for this patient.
Many tree-based ensemble methods exist. As we previously
reported (25), trees with 4 different ensemble methods (i.e.,
bagging, boosting, random forests, and extra trees) have been
tested for RA versus controls and RA versus PsA comparisons.
In the present study, only decision tree boosting that gave
competitive results with the other ensemble methods was
considered (25). Boosting is a standard method (26) in which
the ensemble of trees is built in sequence. Each tree of the
sequence focuses on the data that are misclassified by the
previous trees of the ensemble. More precisely, an AdaBoost
algorithm was used (for review, see ref. 27) with classification
and regression trees (28). Ensembles of 100 trees were con-
structed.
Evaluation of sensitivity and specificity. To obtain an
unbiased estimate of the sensitivity and specificity of a diag-
nosis provided by the boosting algorithm, leave-one-out cross-
validation was used. Using the leave-one-out approach, an
unbiased diagnosis was obtained for each patient by removing
all information concerning this patient (i.e., his or her 2
spectra) from the learning sample, building a model using the
boosting algorithm from the remaining mass spectra, and then
classifying the patient using the boosting model. Because a
patient was described by 2 spectra, a diagnosis may be given in
2 ways using the boosting model: by classifying the 2 spectra
independently from each other or by combining the classifica-
tion of the 2 spectra. In the first case, sensitivity was estimated
by the proportion of the 68 spectra from 34 patients with RA
who were well classified by the boosting classifier, and the
specificity was estimated by the proportion of the 138 spectra
of 69 patients from the control group in whom RA was not
diagnosed. In the second case, because the primary objective is
to maximize sensitivity, a patient was diagnosed as having RA
as soon as 1 of the spectra was classified as RA by the boosting
classifier. Otherwise, the patient was classified as non-RA. The
sensitivity achieved with the 2 combined spectra was then
estimated by the proportion of RA patients who were well
classified according to this rule, and the specificity was esti-
mated by the proportion of patients from the control group in
whom RA was not diagnosed.
Biomarker identification. As a first step to identify
proteins that are potentially involved in RA, m/z peaks or
intervals that are responsible for differentiating RA from
control spectra must be identified. Biomarkers can be identi-
fied individually or by a multivariate analysis.
Univariate analysis. The classic statistical approach to
determining the influence of the classification on the intensi-
ties of some m/z values is to use a statistical test to determine
whether or not the distribution of the intensities at this
position is significantly different in the RA group compared
with the control group. The result of such an analysis is a P
value that determines the probability of getting a more signif-
icant difference than that observed according to the statistical
test. Hence, m/z values corresponding to small P values
highlight significantly different protein concentrations between
the 2 groups. By following the approach adopted (for review,
see ref. 21), the discriminative power of peak values and m/z
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intervals was assessed according to a nonparametric Mann-
Whitney test.
Multivariate analysis. One important characteristic of
decision trees is that it is possible to compute from a tree the
relative relevance or contribution of each variable to the
classification. For each variable, this measure gives the per-
centage of information provided by the tree about the classi-
fication that can be attributed to this variable. The relative
contribution of a variable to an ensemble of trees can then be
obtained by averaging its relative contributions over all trees of
the ensemble. Like the P value, this measure allows m/z values
to be ranked according to their relevance for differentiating
the disease and control groups. However, unlike the P value
approach, which takes into account each variable individually,
this approach considers all variables simultaneously, and hence
it can take into account interactions among variables. Both
approaches may thus provide substantially different results.
The variable importance measure for a tree that we have used
is the Shannon information measure (28). (See ref. 25 for a
more detailed description of this measure in the context of tree
ensembles.)
Western blotting. Myeloid-related protein 8 (MRP-8)
was assessed by Western blot analysis. Briefly, 2 l of serum
was run on 12% Bis-Tris polyacrylamide gels (Invitrogen,
Carlsbad, CA), transferred, and incubated with an anti–MRP-8
monoclonal antibody (1:500 dilution) (Biomedicals AG, Augst,
Switzerland), followed by a mouse secondary antibody (1:5,000
dilution), and MRP-8 was revealed by the enhanced chemilu-
minescence detection method (ECL kit; Amersham Pharmacia
Biotech, Little Chalfont, Buckinghamshire, UK).
Interaction discovery mapping (IDM) affinity beads.
MRP-8 was depleted from RA and control serum samples
using IDM affinity beads (Ciphergen Biosystems) coated with
MRP-8 monoclonal antibody (Biomedicals AG). The experiment
was performed according to the manufacturer’s instructions.
RESULTS
Optimization of the experimental conditions and
reproducibility evaluation. Several parameters have a
large influence on the reproducibility and number of
peaks detected in protein profiles and thus needed to be
optimized. In order to simplify the procedure and to
obtain good reproducibility, serum samples were not
fractionated. In an effort to increase the size of the
proteome examined and to enhance the chance of
detecting protein biomarkers, 103 serum samples were
analyzed in parallel on 2 types of ProteinChip arrays.
The protein profiles obtained on CM10 (cation ex-
change) and H4 (hydrophobic) arrays were found to give
the best results in terms of the number and resolution of
peaks. These profiles, as obtained with the quality
control serum sample, are shown in Figure 1.
Chips corresponding to the 103 serum samples
were read over the course of a week in order to limit
variability across time. Standardization of experimental
conditions was carried out in an effort to minimize the
effects of irrelevant sources of fluctuation, and coeffi-
cients of variation (CVs) were calculated to evaluate the
reproducibility of experiments using the SELDI-
TOF-MS approach. These CV values were obtained by
adding a quality control serum sample on 8 spots of
CM10 or H4 arrays according to the protocol described
in Patients and Methods. The procedure was performed
at the beginning of the study of the 103 serum samples
and again 6 months later. CVs were calculated after the
normalization process by comparing the intensity of 10
common peaks selected throughout the 8 spectra col-
lected from the same array. CVs were also established by
comparing interchip variation at an interval of 6 months.
Intravariation of CM10 and H4 arrays were evaluated to
be 9% and 16.6%, respectively, at the beginning of the
study and 12% (CM10 array) and 20% (H4 array),
respectively, 6 months later. Interchip variation across
time was determined to be 20% and 25% for the CM10
and H4 arrays, respectively.
Figure 1. Protein mass spectra of a quality control serum sample from a healthy control subject,
obtained on CM10 and H4 arrays. The intensity versus mass/charge (m/z) values are shown.
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Figure 2 shows 3 spectra for a quality control
serum sample on CM10 array, before starting the ana-
lysis and 6 months later. These spectra show similar
protein profiles, which demonstrate the standardization
of our experimental procedure over time.
At least 30 samples from each of the 3 classifica-
tion groups (RA, inflammation control, and negative
control) were profiled in a standardized manner. This
number of samples was sufficient to give 90% statisti-
cal confidence in a single marker, with P values less than
0.01, and was also sufficient to allow use of different
forms of multivariate analysis.
Data analysis. Two hundred six spectra (each
serum sample was loaded in duplicate) from 103 serum
samples were collected on each array (CM10 and H4).
Peak detection and alignment resolved 140 peaks on
CM10 arrays and 104 peaks on H4 arrays in the mass
range of 1–20 kd. In contrast, the proportional integra-
tion of the mass range yielded 1,026, 628, and 319 mass
intervals, respectively, for r  0.3%, r  0.5%, and r 
1%. This corresponded in each case to the number of
input features provided to the boosting algorithm.
Sensitivity and specificity. RA spectra were first
compared with control spectra (inflammation and non-
inflammation controls). Table 2 shows the sensitivity/
specificity values estimated by decision tree boosting on
both surfaces, with different r values and integrated
peaks. Sensitivities of 69–78% and 81–85% for classify-
ing individual spectra were obtained on CM10 and H4
arrays, respectively. Taking into account the 2 spectra
corresponding to 1 patient, the sensitivity rose to a range
of 79–91% on CM10 and 88–97% on H4. However, the
specificities of 78–90% and 91–95% on CM10 and H4
arrays, respectively, were slightly decreased with 2 com-
bined spectra, to 75–85.5% on CM10 array and 87–91%
on H4 array.
RA spectra were also compared with PsA spec-
tra. As shown in Table 3, the sensitivities for classifying
individual spectra were 84–90% on CM10 array and
Figure 2. Reproducibility of the protein profile spectra of the quality
control serum sample on the CM10 arrays, as demonstrated before
starting the analysis of the 103 serum samples from patients and
healthy controls (spectra A–C) and 6 months later (spectra D–F).
Table 2. Sensitivities and specificities obtained by decision tree
boosting analysis on CM10 and H4 arrays according to different
preprocessing approaches, for patients with RA versus controls*
Preprocessing
approach
2 independent spectra 2 combined spectra
Sensitivity Specificity Sensitivity Specificity
CM10
r  0.3% 78 90 88 85.5
r  0.5% 76.5 87 91 77
r  1% 78 88 91 84
Integrated peaks 69 78 79 75
H4
r  0.3% 85 91 94 87
r  0.5% 85 91 94 90
r  1% 84 95 97 91
Integrated peaks 81 93 88 90
* Values are the percent. Two approaches were used, as follows:
classifying 2 spectra from the same patient independently of each
other, and combining classification of the 2 spectra. RA  rheumatoid
arthritis.
Table 3. Sensitivities and specificities obtained by decision tree
boosting analysis on CM10 and H4 arrays according to different prepro-
cessing approaches, for patients with RA versus patients with PsA*
Preprocessing
approach
2 independent spectra 2 combined spectra
Sensitivity Specificity Sensitivity Specificity
CM10
r  0.3% 84 62 85 48
r  0.5% 84 64 88 38
r  1% 90 71 85 33
Integrated peaks 87 55 94 48
H4
r  0.3% 93 79 97 67
r  0.5% 94 86 97 76
r  1% 90 76 94 71
Integrated peaks 94 83 91 71
* Values are the percent. Two approaches were used, as follows:
classifying 2 spectra from the same patient independently of each
other, and combining classification of the 2 spectra. RA  rheumatoid
arthritis; PsA  psoriatic arthritis.
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90–94% on H4 array. Again, combining the duplicates
improved sensitivity (85–94% on CM10 and 91–97% on
H4). However, combining the duplicates decreased the
specificity considerably.
Biomarker classification. RA versus non-RA con-
trol group. Table 4 presents the most discriminant m/z
intervals or peaks provided by the boosting algorithm
and by P value analysis for the 2 preprocessing ap-
proaches: mass intervals (r  0.3% or r  0.5%) and
integrated peaks. For each m/z value, the first number
represents the percentage of information attributed to
this value (these numbers sum to 100% over all features)
based on the multivariate analysis (decision tree boost-
ing analysis). The second number is the rank of this m/z
value when all m/z values are ordered according to the P
value. It was observed that for a given preprocessing
approach, the most discriminant m/z values provided by
the multivariate analysis were not necessarily identical to
those provided by the P value. This was particularly
obvious on CM10 arrays, where the most discriminant
mass range according to boosting (around 1,816 daltons)
was not well ranked according to the P values (rank 594
with r  0.3%, and rank 74 with r  0.5%). The 2
preprocessing approaches may also highlight different
m/z values for a given statistical approach. As an exam-
ple, the m/z range around 1,816, which was ranked as the
first value using the boosting analysis on CM10 with the
mass interval preprocessing approach, was not ranked
with peak integration analysis.
Nonetheless, a careful analysis of the generated
data allowed us to focus our attention on peaks high-
lighted by the 2 preprocessing procedures, by the 2
statistical analyses, or by both approaches. For example,
the m/z range around 2,924 daltons was considered as
the most relevant value for discriminating RA versus
controls on H4 arrays. Indeed, it was first according to
multivariate analysis (% information) and P value (rank)
analysis (r  0.5% and integrated peaks), but also was
second in percentage and the first with r  0.3%.
Concordance between boosting analysis and P value
analysis was also found for m/z  10,832 on CM10
arrays, using integrated peaks as the preprocessing ap-
proach. Figure 3 illustrates this potential biomarker.
According to the results obtained in previous
studies (29,30), the 10,832 peak visualized by SELDI-
TOF in serum from patients with RA was suspected to
be MRP-8. In order to confirm this hypothesis, serum
samples obtained from 1 healthy person and from 1
patient with RA were subjected to Western blotting.
MRP-8 was detected (by MRP-8 monoclonal antibody)
Table 4. Most discriminant mass/charge (m/z) values obtained on


























































* Relative contribution of a mass/charge value, by multivariate analy-
sis.
† According to P value.
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in the serum from the patient with RA but not in the
control (Figure 4a). The presence of MRP-8 was further
confirmed in all other RA sera tested (n  8), in 4 of the
8 PsA sera tested, and in none of the 8 negative control
sera tested. This identification of MRP-8 was correlated
with the presence of the 10,832 peak in the correspond-
ing spectra obtained by SELDI-TOF.
In a second experiment, we carried out depletion
of MRP-8 from RA serum by using IDM affinity beads
coated with MRP-8 monoclonal antibody. As shown in
Figure 4b, the peak intensity of 10,832 decreased after
serum depletion (spectra C and D) compared with the
crude RA serum sample (spectra A and B) and the
quality control serum sample (E).
Our data suggest that the 10,832 peak could be
MRP-8. However, definitive identification of this peak
will be obtained only by MS/MS analysis. The m/z values
around 11,630 (Figure 3) were also rather well classified
when determining its relative position according to
preprocessings and statistical analysis.
RA versus PsA group. Table 5 illustrates the most
discriminative m/z intervals when comparing the RA group
versus the PsA group. The m/z around 4,824 was perfectly
classified according to the 2 preprocessing approaches and
the 2 statistical analysis on H4 arrays, whereas the m/z
around 4,666 was also of interest on CM10 arrays.
Association with anti-CCP positivity. Using mul-
tivariate analysis according to the 2 combined spectra
approach, sensitivity ranged from 79% to 97% (Tables 2
and 3), with a mean of 91%. This value was therefore
chosen to represent the sensitivity of the proteomic
analysis of RA sera. Thus, 31 of 34 RA sera were
considered positive. Among the RA sera, 28 of 34 were
anti-CCP positive. Positivity by proteomic analysis was
associated with positivity by anti-CCP testing, as shown
by calculation of an odds ratio of 13.5 (95% confidence
interval 1–185). In an attempt to study quantitative
correlations between proteomic analysis and anti-CCP
positivity, we plotted the intensity of the 10,832 peak of
RA serum samples (n  34), one of the major biomar-
Figure 3. Potential biomarkers (m/z  10,832, 11,632, and 11,706) on CM10 array, distinguishing patients with
rheumatoid arthritis (RA) from controls. a, Mean values of all spectra. The black and grey lines represent values
for controls and RA patients, respectively. b, Gel view of spectra for samples collected from 10 controls and 10
patients with RA.
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kers, against the log of anti-CCP antibody concentra-
tions (as detected by ELISA) and observed a significant
positive linear correlation (r  0.435; P  0.01).
DISCUSSION
In this study, we used methodology based on
SELDI-TOF-MS and decision tree boosting analysis, in
adequately controlled patient groups, to select new
biomarkers for RA. Based on our results, we propose a
pattern of protein peaks that are specific to RA and
independent of the inflammatory process and of puta-
tive concomitant therapies. Indeed, the RA and the PsA
groups shared many epidemiologic characteristics, in-
cluding similar disease duration, clinical disease activity,
serum CRP levels, and a comparable percentage of
patients receiving MTX.
SELDI-TOF-MS is a new proteomic approach
that allows multiple serum samples to be analyzed in a
relatively short time. This analysis is based on a compar-
ison of protein profiles between 2 sample groups. Up-
regulated or down-regulated proteins are underlined
and characterized as potential biomarkers according to
several statistical analyses.
However, special care must be applied in order to
optimize the reliability and reproducibility of proteomic
patterns obtained by SELDI-TOF-MS. Indeed, varia-
tions due to sample collection, data preprocessing, and
statistical analysis can be problematic (31–33), giving
Figure 4. a, Detection of myeloid-related protein 8 (MRP-8) by
Western blotting in serum from 1 normal control (NC) and 1 patient
with rheumatoid arthritis (RA). b, Depletion of MRP-8 from RA
serum by using interaction discovery mapping (IDM) affinity beads
coated with MRP-8 monoclonal antibody. A and B show a crude serum
sample from a patient with RA; C and D show an RA serum sample
after MRP-8 depletion with IDM beads; E shows a crude serum
sample from a healthy control.
Table 5. Most discriminant mass/charge (m/z) values obtained on
CM10 and H4 arrays for patients with rheumatoid arthritis versus








































* Relative contribution of a mass/charge value, by multivariate analy-
sis.
† According to P value.
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rise to artifacts. Hence, the impact of freeze–thaw cycles
on protein profiles must be well considered, standard
protocols must be developed to minimize unwanted
fluctuation, and CVs between ProteinChips must be
calculated by using common peaks across different spec-
tra. Chip variability was controlled by using chips from
the same lot, and the chemicals used during a given
experiment were from the same batch. Matrix composi-
tion and instrument settings are extrinsic factors that
also influence reproducibility and must be optimized.
Calibration of the instrument must be performed fre-
quently. Finally, normalization, baseline subtraction,
and peak detection are processing steps that must be
well achieved.
To avoid variation in the procedure, freshly col-
lected sera were immediately aliquoted, stored at
80°C, and thawed only once. Use of quality control
serum allowed detection of any unusual features during
the process. Such precautions led to very good repro-
ducibility of the protein peak patterns.
One of the challenges in the analysis of SELDI-
MS–generated data is to avoid the false discovery of
protein peaks with a discriminatory power due to ran-
dom variation. A safeguard against this problem lies in
the choice of the machine learning algorithm and the
validation method. Several decision tree–based ensem-
ble methods were tried, and boosting was found to be
among the best alternatives for this kind of problem
(25). The k-nearest neighbors method and support vec-
tor machines with linear kernels were also applied, but
none of these methods was able to reach the same level
of sensitivity and specificity as that associated with
decision tree boosting. Furthermore, a very important
advantage of boosting and other ensemble methods with
trees is the ability to estimate from the trees the
contribution of each variable to the classification. Al-
though single decision trees are also able to select
relevant variables, the ranking provided by an ensemble
of trees is usually much more robust.
Special care was also taken in choosing the
validation method. Leave-one-out cross-validation en-
sured an unbiased estimate of the sensitivity and speci-
ficity of our classifier. Hence, because boosting reaches
high sensitivity and specificity values under leave-one-
out, we can be quite confident in the best biomarkers
that were proposed by this method.
Preprocessing was also an important step in
avoiding detection of artifacts. We systematically com-
pared 2 preprocessing procedures, mass intervals and
integrated peaks, on 2 different arrays, CM10 and H4,
and obtained good and comparable sensitivity and spec-
ificity values. In this study, all samples were examined in
duplicate. The results with boosting showed that the
combination of 2 spectra per patient at the time of
diagnosis can significantly improve sensitivity without
losing too much specificity.
We next conducted our analysis toward classifi-
cation of the biomarkers by using 2 statistical ap-
proaches, a univariate (P value) and a multivariate
(decision tree boosting) analysis on the 2 preprocessings.
If a value of r  1% in the mass interval method usually
gives the best sensitivity and specificity values, these
mass intervals are too high to identify a single biomarker
with sufficient accuracy for further analysis. As a result,
only the lower values of r  0.3% and r  0.5% were
selected for this task.
Several m/z values were identified as biomarkers
specific for RA. The likelihood for a peak to be a
biomarker is increased if it has been well classified on
the basis of the 2 statistical analyses and 2 preprocess-
ings. This situation was encountered, and also con-
firmed, in the 2 comparisons (RA versus non-RA and
RA versus PsA) with both arrays. However, variations in
the biomarker classification may also be observed. Dis-
crepancies linked to statistical analyses can be explained
as follows. The comparison between boosting variable
classification and P values shows the interest of a
multivariate analysis in identifying biomarkers. Indeed,
the discriminative power of some m/z values appears
only when they are combined with each other. Variables
that correspond to elevated P values can be identified
only by multivariate analysis. Discrepancies linked to
data processing can be explained by the fact that peak
detection may filter out potentially important biomark-
ers, even with an optimal setting of the Biomarker
Wizard software, as was observed for the m/z value of
1,816. This value was first classified on CM10 for
discriminating RA versus control, whereas it was not
selected from among the 140 peaks with peak detection.
At least 2 proteomic studies in RA have been
previously published; 1 of these studies focused on
serum (34), and the other focused on synovial fluid (29).
In the first study, using a 2-D gel approach, -enolase
was proposed as a biomarker for RA (34). In the second
study, which used the same SELDI-TOF-MS technology
as that used in our study, several biomarkers discrimi-
nating between RA and osteoarthritis, particularly
MRP-8, were identified (29). Recently, this MRP-8 was
confirmed by MS/MS to be present in serum of patients
with erosive RA (30).
Due to our experimental conditions with a cutoff
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of 20,000 daltons, it is clear that our biomarker classifi-
cation does not include -enolase, whereas MRP-8
(MW 10,850) could have been detected. Preliminary
results obtained by Western blotting and IDM affinity
beads coated with MRP-8 antibody have suggested that
the 10,832 peak observed in our RA patients could be
the MRP-8 protein. MRP-8 is, however, not totally
specific to RA, and is also observed in serum and
synovial fluid from patients with active juvenile RA (30)
as well as in the inflamed synovial tissue of patients with
RA and patients with spondylarthropathy (35). It was
also shown in our study that the 10,832 peak was not a
discriminant value in the comparison by SELDI-TOF
and boosting analysis of patients with RA versus patients
with PsA. Because MRP-8 is specifically released by
activated monocytes upon interaction with activated
endothelial cells under inflammatory conditions (30), it
could merely represent an excellent marker of the early
inflammatory process. This finding highlights the neces-
sity of using several biomarkers for optimizing a specific
diagnosis of RA. Other purification procedures for
identification of the most specific RA biomarkers are
currently being investigated.
However, even without the purification of several
protein peaks selected as specific biomarkers for RA,
SELDI-TOF-MS technology allowed us to quickly ana-
lyze 100 serum samples, using decision tree boosting
analysis as the main statistical method and a previously
proposed pattern of protein peaks specific for RA. The
potential clinical relevance of our results is further
highlighted by the statistical correlations observed be-
tween the positivity of RA sera for the proteomic
analysis and their positivity for the anti-CCP test, as well
as the correlations between the intensity of the 10,832
peak and anti-CCP antibody concentrations. The bio-
logic significance of such correlations remains unknown,
however. The relevance of this proteomic technique for
the diagnosis of RA remains investigational, but the
existence of serum-based marker panels with sufficient
sensitivity and specificity could facilitate the screening of
individuals at high risk for developing RA, favor early
identification of the disease, and allow us to predict the
response to therapeutic agents. Validation of our first
model with a complete independent set of samples
collected in different institutions according to our stan-
dardized procedure is in progress. Moreover, for a better
understanding of RA disease, identification of the most
specific biomarkers described in this report would be of
great interest.
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